Topics:
Genitourinary Cancers • Medical Oncology
Is it safe to administer cabazitaxel to a patient with mCRPC who developed grade 3 pneumonitis from docetaxel?
Are there any precautions or pre-medications that may permit this treatment in patients who are fit for therapy but have exhausted all other treatment options?
Answer from: Medical Oncologist at Academic Institution
In general, the answer is yes, as these are distinct therapies with distinct toxicities. Both are formulated in TWEEN80 solvent and can cause allergic reactions and anaphylaxis, and this is the only adverse event that I would strongly consider avoiding cabazitaxel if this event was experienced in a ...
Sign in or Register to read more